AdvanDx receives clearance  from the US Food and Drug Administration (FDA) for 90 minutes PNA FISH Protocol for identifying Gram-negative bloodstream pathogens.

AdvanDx has announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its E.coli/P. aeruginosa PNA FISH and EK/P. aeruginosa PNA FISH tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes and thereby help clinicians further improve pseudomonal vs. non-pseudomonal antibiotic selection for patients with Gram-negative bloodstream infections.

Read more

 


 

More news

(2011-12-21)
(2011-07-08)
(2011-02-28)
(2010-12-21)
(2010-11-30)
(2010-11-26)
(2010-11-22)
(2010-09-20)
(2010-06-17)
(2010-03-19)
(2009-08-21)
(2007-05-09)
 
 
News type
 
 

Latest PE Voice

Harald Mix on Nordic private equity

- 1/10/2012 10:10:00 AM
At the Argentum Conference in 2010, we asked Harald Mix, Managing Partner and Co-founder of Altor Equity Partners about the outlook for future returns in Nordic private equity.
 
 

Calendar

2012-02-16 in Bergen

Vestlandskonferansen

2012-02-27 in Berlin

SuperReturn International 2012

2012-03-05 in Copenhagen

Nordic Fundraising Summit

2012-03-14 in Geneva

EVCA Investors' Forum

2012-03-15 in La Clusaz

EVCA Networking Event 2012
 
Copyright Argentum 2009